AbbVie 2025 results
2025 Financial Performance Summary: AbbVie’s Strategic Transition Robust Revenue Growth Driven by New Core Assets AbbVie delivered a strong performance in 2025, with full-year net revenues reaching 61.16 billion, representing an 8.6% year-over-year increase. This growth is particularly significant as it marks the second full year following the loss of exclusivity for Humira in the […]
Abbvie’s recent M&As in 2024-2025
Since we are looking at this from a Financial Analysis and M&A Strategy perspective, the AbbVie/Capstan deal is a classic example of a “Platform Play” aimed at replacing a declining cash cow (Humira) with high-moat technology. Here is the strategic breakdown of the acquisition: 1. Strategic Context: The “Humira Cliff” AbbVie has been the king […]
Abbvie – 2025Q3 report
Despite overall revenue growth, AbbVie reported a significant decline in net income due to substantial business acquisition costs, research and development (R&D) licensing fees, and asset impairments. 1. Financial Results Overview 2. Core Products and Therapeutic Area Performance The company’s revenue structure is undergoing a major transition as growth in new immunology drugs offsets the […]
Abbvie – Competitions
Here is the competitive technical analysis and revenue breakdown for AbbVie’s primary products. 1. Immunology: The “New Generation” Duo With Humira facing biosimilar erosion, AbbVie has successfully pivoted to Skyrizi and Rinvoq. These two products now represent the cornerstone of the company’s growth. 2. Medical Aesthetics: The Botox Moat Despite rising competition, AbbVie (via Allergan) […]
Abbvie – History
The history of AbbVie can be categorized into three distinct phases, transitioning from a spinoff to a global pharmaceutical powerhouse. Phase 1: Independence and the Humira Era (2013-2018) AbbVie officially separated from Abbott Laboratories on January 1, 2013, to focus on research-based biopharmaceuticals. Core Technologies: Revenue Levels: Phase 2: Massive Diversification (2019-2022) Anticipating the patent […]